Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

Table 3

In-study trends in laboratory parameters associated with the metabolic syndrome (secondary efficacy endpoints). All results expressed as mmol/L unless indicated otherwise. Data are expressed as mean ± SD.

Total patients	𝑁=5603
Fasting plasma glucose
At study start	6.8 ± 2.1
At study end	6.2 ± 1.6
In-study change	−0.8 ± 1.6
Triglycerides
At study start	2.4 ± 1.1
At study end	2.0 ± 0.9
In-study change	−0.6 ± 1.0
Cholesterol
At study start	5.8 ± 1.1
At study end	5.2 ± 0.9
In-study change	−0.7 ± 1.0
HDL-cholesterol
At study start	1.2 ± 0.5
At study end	1.3 ± 0.5
In-study change	0.1 ± 0.5
LDL-cholesterol
At study start	3.5 ± 1.1
At study end	3.0 ± 0.9
In-study change	−0.5 ± 0.9
Creatinine
At study start	0.09 ± 0.06
At study end	0.10 ± 0.07
In-study change	0.01 ± 0.04
Urinary albumin
At study start	92.7 ± 191.6
At study end	83.3 ± 205.5
In-study change	−7.6 ± 153.1
Body weight (kg)
At study start	92.0 ± 15.6
At study end	90.0 ± 15.3
In-study change	−2.1 ± 5.4